已收盤 08-07 16:00:00 美东时间
+0.070
+0.97%
礼来在最新的财报中上调了2026年销售指引,公司的减重药业务在第二季度表现远超预期,缓解了投资者对于“减肥药热潮正在降温”的担忧。 礼来周三表示,公司预计20...
08-05 23:48
Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient Care NEW YORK, July 21, 2026 /PRNewswire/ -- Market News UpdatesNews Commentary - Globally...
07-21 20:30
今日重点评级关注:Needham:维持Immuneering"买入"评级,目标价从11美元升至18美元;富瑞:维持塞德斯医疗"买入"评级,目标价从90美元升至100美元
07-21 11:36
今日重点评级关注:摩根大通:维持联合大陆航空"超配"评级,目标价从156美元升至203美元;摩根士丹利:维持联合大陆航空"超配"评级,目标价从185美元升至190美元
07-20 13:49
迷幻药企业ATAI劲升近40%!获礼来38亿美元收购;PayPal升22%,拟获Stripe斥资530亿美元收购;AI交易集体熄火,费城半导体指数跌入熊市,闪迪重挫29%>>
07-18 10:30
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Jefferies analyst Andrew Tsai downgraded AtaiBeckley Inc (NASDAQ:ATAI) from Buy to Hold and cut t...
07-17 21:40
Guggenheim analyst Eddie Hickman downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Neutral.
07-17 20:29
ATAI飙升33%,获礼来溢价收购,旗舰药物已获FDA突破性疗法认定;万宝盛华劲升32%,Q2业绩超预期;雅培升逾10%,Q2诊断业务大幅增长,上调全年业绩指引>>
07-17 19:18
今日重点评级关注:瑞杰金融:维持Electrovaya"强力买入"评级,目标价从14美元升至22美元;BTIG:维持vTv Therapeutics"买入"评级,目标价从49美元升至57美元
07-17 11:35
Canaccord Genuity analyst Sumant Kulkarni downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and announces $8 price target.
07-17 03:55